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A 63-year-old white male was admitted to the hospital because of
renal insufficiency. He recently had been treated at another hospital for
bleeding peptic ulcer disease. He had had two or three episodes of gross
hematuria dating back to approximately 10 years prior to admission and
had had a gradual decline in renal function over the previous 3 years,
The medical history was remarkable for a previous episode of upper
gastrointestinal bleeding secondary to duodenal bulb ulcer, and hyper-
tension for at least the previous 10 years that had been controlled
intermittently with medication. The family history was negative for
renal disease.
Physical examination revealed a blood pressure of 170/105 mm Hg; he
was afebrile. Urinalysis showed 3+ protein; 20—30 red blood cells/high-
power field, and rare white blood cells; the 24-hour urine protein was
1.6 g. Other laboratory values included blood urea nitrogen (BUN), 39
mg/dl; serum creatinine, 3.4 mg/dl; glucose, 82 mg/dl; sodium, 135
mEq/liter; potassium, 3.7 mEq/liter; chloride, 100 mEq/liter; bicarbon-
ate, 25 mEq/liter; hematocrit, 32.5%; hemoglobin, 6.8 mg/dl; and
platelet count, 340,000 mm3. The PT, PTT, and liver enzymes were
normal. A repeat 24-hour urine collection revealed a creatinine clear-
ance of 14.4 mI/mm and 2.3 g protein. The C3, C4, and CH5O were
normal, and the sedimentation rate was 40 mm/hr. The rheumatoid
factor and ANA were negative, as were the antineutrophilic cytoplas-
mic antibodies.
A renal biopsy specimen examined by light microscopy revealed 8 of
13 glomeruli to be scierosed. Three glomeruli showed mesangial hyper-
plasia, matrix expansion, and crescents with synechiae. Many glomer-
ular capillaries were narrowed or obliterated. Immunofluorescent ex-
amination revealed 3+ granular IgA, 3+ LgG, and 2+ C3 deposits.
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Electron microscopy revealed electron-dense deposits in the mesangial
matrix. Areas of modest interstitial cell infiltrate, extensive interstitial
fibrosis, and tubular atrophy were present. A diagnosis of IgA nephrop-
athy was made.
The patient's blood pressure was controlled with medications, but his
renal function continued to deteriorate. One year after discharge, the
BUN and serum creatinine were 55 mg/dl and 5.0 mg/dl, respectively.
Discussion
DR. HANNA E. ABBOUD (Professor and Chief, Division of
Nephrology, The University of Texas Health Science Center,
and Staff Physician, Audie Murphy Veterans Administration
Hospital, San Antonio, Texas): This patient has IgA nephrop-
athy, a disease that accounts for approximately one-third of all
cases of primary glomerular disease and is regarded as the most
common form of primary glomerulonephritis worldwide. IgA
nephropathy is thought to be an immune-complex-mediated
disease in which circulating IgA-containing immune complexes
are deposited in the mesangium. Autoimmune mechanisms
recently have been incriminated in this and other forms of
glomerulonephritis. IgA nephropathy is associated with a pro-
liferative form of glomerulonephritis, which is characterized by
hypercellularity and expansion of the mesangium; it can be
accompanied by crescent formation. Recent studies have
clearly documented the infiltration of activated lymphocytes
and monocytes-macrophages in the glomerulus and the intersti-
tium. Interstitial cell infiltration occurs in most if not all
patients; glomerular infiltration with these inflammatory cells is
present predominantly in patients with crescent formation.
Poor prognostic indicators of the disease include heavy protein-
uria, hypertension, and severe mesangial cell proliferation with
crescent formation. The utility of laboratory tests as prognostic
indicators remains unproven; serum IgA concentrations and
levels of IgA-containing circulating immune complexes do not
correlate well with clinical outcome [1].
The immune-mediated, inflammatory glomerular diseases are
characterized by a spectrum of morphologic and functional
changes that involve both the glomerulus and the interstitium
[1—3]. These diseases, progressive in nature, distort the normal
architecture of the nephron and eventually reduce renal func-
tion [4, 5]. The pathogenesis of this group of diseases has been
under intensive investigation in the last decade, and a clear role
both for humoral and cell-mediated immune mechanisms is
becoming increasingly evident [3, 6]. Unfortunately, despite
these advances, therapy for this group of diseases remains
empiric, risky, and often futile. The pathologic manifestations
of glomerular diseases are diverse, ranging from subtle morpho-
logic changes to severe cellular inflammatory reactions. In
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Table 1. Established or postulated role of cytokines in renal
pathology
Growth regulation: hypertrophy of the glomerulus and/or glomerular
or tubular cells, proliferation of glomerular or tubulointerstitial
cells or infiltrating inflammatory cells
Regulation of matrix component synthesis or degradation including
changes in basement membranes, and development and progression
of fibrosis
Modulation of the immune inflammatory response through
chemotaxis, migration, activation, or suppression of inflammatory
or intrinsic glomerular cell responses
Regulation of vascular tone with subsequent changes in blood flow
and glomerular filtration rate
Development and differentation
Table 2. Suggested criteria implicating a particular cytokine in renal
pathology
Ability to elicit a biologic function relevant to renal pathology in any
target cell or tissue
Presence of functional receptors for a cytokine in freshly isolated
tissue such as glomeruli, tubules, or cultured glomerular and
tubular cells
Cytokines can induce one or more pathologic manifestations upon
in-vivo administration or when overexpressed, as in transgenic
animals
Temporal relationship between the expression of cytokines and
pathologic manifestation of the disease process
Attenuation or abolition of disease manifestation upon neutralization
of biologic effect of cytokines
many instances, however, these diseases are relentlessly pro-
gressive and result in a complete loss of renal function. Mesan-
gial matrix expansion and some hypercellularity occur com-
monly in all chronic progressive glomerular diseases; this
pattern of glomerular pathology is seen in advanced renal
failure of any cause [2, 4, 5]. Several mediators have been
incriminated in the pathogenesis of these morphologic and
functional changes [3, 4, 7]. However, in most instances, the
presumption of a pathogenetic role is based on a descriptive
association or on the known effects of these mediators in other
systems. Among the mediators that have attracted recent
attention are polypeptide growth factors or cytokines [8—16].
Throughout my discussion, I will use these two terms inter-
changeably.
Evidence is emerging that cytokines are involved in the
mediation of the structural and functional abnormalities that
occur in glomerulonephritis and progressive forms of glomeru-
lar and interstitial injury. The cytokines constitute a group of
low-molecular-weight (<80 kD), potent regulatory peptides
with multiple and often overlapping biologic activities. They
interact in complex cell- and tissue-specific networks. Their
effects are mediated through high-affinity receptors on target
cells; these receptors are expressed constitutively or are induc-
ible [8—16]. Cytokines play a role in a wide variety of biologic
processes including hypertrophy; proliferation; regulation of
matrix synthesis and degradation; immune inflammatory re-
sponses; development and differentiation, and regulation of
vascular tone. When one considers the multiple biologic effects
of these ubiquitous compounds, their potential involvement in
the glomerular and interstitial abnormalities of glomerulone-
phntis comes as no surprise. Glomerular involvement during
the course of glomerulonephritis entails one or more of the
following: hypercellularity due to intrinsic cellular proliferation,
hypercellularity due to infiltration and proliferation of inflam-
matory cells, and an increase in the mesangial cell matrix due to
injury to one or more types of glomerular cells (for example,
epithelial or mesangial). The glomerular lesions usually are
accompanied by an increase in capillary permeability, which is
manifested clinically as proteinuria. In addition, hemodynamic
abnormalities are usually present. Depending on the severity
and stage of the disease, these abnormalities can decrease or
increase glomerular blood flow, filtration rate, and hydrostatic
pressure. The interstitium is involved very early in almost all
glomerular diseases [2]. Cellular infiltrates in the interstitium
are often more pronounced than they are in the glomerulus.
Tubular and vascular dysfunction and injury eventually
progress to interstitial fibrosis and tubular atrophy [2, 16]. The
recent availability of renal, and specifically glomerular, cells in
culture has stimulated an exploration of the role of cytokines in
glomerular disease [17, 18]. Table 1 lists the potential role of
cytokines in renal pathologic manifestations of glomerulone-
phritis.
Among the polypeptide growth factors, platelet-derived
growth factor (PDGF) [19, 20], transforming growth factor beta
(TGF/3) [13, 21], and insulin-like growth factor-l (IGF1) [22] are
prime candidates as mediators of acute and chronic glomerular
injury. Excellent evidence also exists indicating that interleu-
kin-6 (IL-6), interleukin-1 (IL-i), and tumor necrosis factor
alpha (TNFa) mediate, in part, immune-mediated glomerular
and/or interstitial injury [16]. The results of recent in-vitro
studies also suggest that some cytokines such as monocyte
chemotactic peptide (MCP-1), macrophage colony-stimulating
factor (M-CSF), interleukin-8 (IL-8), and gamma interferon
(y-IFN) are involved in the early phase of renal injury [16].
Additional in-vitro studies utilizing cultured glomerular cells
and tubular epithelial or interstitial cells suggest that epidermal
growth factor (EGF) [23—25], transforming growth factor alpha
(TGFa) [11], and basic fibroblast growth factor (bFGF) [11, 25,
26] also can mediate renal injury.
I believe that additional evidence beyond the mere presence
of a given cytokine must exist before it can be invoked as a
mediator of the structural and functional changes in glomerulo-
nephritis (Table 2). For example, does the cytokine in question
elicit a similar biologic effect to that postulated for the kidney in
some other tissue or cultured cell type? Second, is there
evidence for the presence of functional receptors known to
mediate certain biologic effects of a particular cytokine in
freshly isolated glomeruli, cortical tissue, or cultured glomeru-
lar or extraglomerular cells? Third, does the cytokine induce
one or more of the pathologic manifestations when it is admin-
istered in vivo or when it is overexpressed in transgenic
animals? Fourth, is there evidence of a temporal change (in-
crease or decrease) in the expression of the active cytokine
and/or its receptor in vivo appropriate to the postulated patho-
logic manifestations? Fifth, and perhaps most definitive, does
administration of an antagonist or neutralizing antibody of the
cytokine or its receptor attenuate or abolish the disease mani-
festation? The best evidence to date comes from studies in
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Table 3. Biologic sources of growth factors
Monocytes-macrophages Platelets Lymphocytes Renal tissue
PDGF Activated monocytes or tissue Release primarily HIV infected Mesangial cells express A & B
macrophages PDGF
AB (80%)
BB (15%)
chains and release
predominantly AA isoform
Endothelial cells express A
and B chains and release
PDGF
Collecting duct cells release
PDGF
TGF-beta Active TGF-beta in response Release latent Release latent Glomeruli express TGF-beta 1
to y-IFN, 1,25 vit D, and TGF-beta TGF-beta and 2 mRNA and protein
retinoic acid Mesangial and endothelial cells
release latent TGF-beta
IGF1 Activated monocytes and Mesangial and endothelial
macrophages cells, collecting duct cells
IL-I Activated monocytes and Release IL-i beta Activated mesangial cells
macrophages
IL-6 Activated monocytes When activated Mesangial cells stimulated with
lipopolysaccharide
TNF Activated monocytes and Mesangial cells stimulated with
macrophages iipopolysaccharide
human renal tissue and in animal models of renal disease; these
studies suggest that PDGF, TGF/3, IGF1, IL-i, IL-6, and TNF
mediate hypercellularity, matrix expansion, and other patho-
logic manifestations of some forms of glomerulonephritis or
progressive glomerular injury. In many instances, however, the
evidence is largely descriptive and relies simply on the associ-
ation of increased or decreased expression of cytokines during
the course of a disease.
The precise source of the polypeptide growth factors impli-
cated in various renal diseases is important because this infor-
mation likely has therapeutic as well as pathogenetic implica-
tions. Most of these compounds are stored or synthesized in
infiltrating inflammatory cells [26—30]. In addition, many of
these peptides are synthesized by intrinsic glomerular cells [16,
31—37]. Hence these compounds could play a role both in
immune inflammatory and noninflammatory renal diseases.
Such a distinction, however, is becoming arbitrary now that
careful immunohistochemical techniques using specific markers
have identified mononuclear inflammatory cells, including
monocytes and lymphocytes, in traditionally "noninflammato-
ry" lesions [28]. Activated platelets, monocytes, tissue macro-
phages, and lymphocytes "passing through" or infiltrating the
kidney could release substantial amounts of these peptides. On
the other hand, cytokine release by intrinsic glomerular cells or
extraglomerular cells suggests their involvement even in late
phases of glomerulonephritis when the acute inflammatory
process has subsided, or even in the so-called "noninflamma-
tory" glomerular diseases [5]. Table 3 lists the site of produc-
tion of some of the cytokines. Whereas cytokines such as IL-i,
TNF, IL-6, EGF, and IGF1 are found in the systemic circula-
tion, mounting evidence suggests that they do not primarily
function in an endocrine manner, but rather in an autocrine or
short-range, paracrine manner.
I will focus the remainder of my discussion on the role of
selected cytokines. Because our primary interest is in under-
standing the pathogenesis of individual disease entities, the
ideal format would be to discuss a given disease and the role of
various cytokines in mediating its pathologic manifestations.
Unfortunately, such an approach is not yet possible because of
the paucity of detailed chronologic studies in experimental
disease models and of the very limited information from human
tissue.
Platelet-derived growth factor
Biologically active PDGF, the most potent mitogen for me-
sangial cells, is a disulfide-linked dimer composed of two
polypeptide chains, designated A and B, that are encoded by
two separate genes [14, 15]. Recent evidence disclosed that
PDGF exists in three biologically active forms: PDGF AB, AA,
and BB [38]. The PDGF stored in human platelet alpha granules
is predominantly PDGF AB (approximately 80%); less than
20% is PDGF BB [38]. Activated monocytes or tissue macro-
phages, as well as glomerular mesangial and endothelial cells,
release PDGF [27, 36—40]. Among the several peptide growth
factors, as I noted, PDGF stands out as the most potent mitogen
for mesangial cells [25, 36, 37]. Mesangial cells not only respond
to PDGF but, as I said, they also are a source of this peptide
[32, 36, 37]. Mesangial cells isolated from glomeruli of several
species, including the human, rat, and mouse, express PDGF
A- and B-chain mRNA and produce PDGF [37, 41]. The PDGF
mRNA and protein also are highly expressed in microvascular
endothelial cells isolated from human kidneys [39, 40]. Serum,
as well as several purified recombinant growth factors, stimu-
late DNA synthesis and induce PDGF A- and B-chain mRNAs
in mesangial cells [37], The induction of PDGF genes and the
production of PDGF in response to several peptide growth
factors raise the possibility that endogenous PDGF derived
from mesangial cells mediates the mitogenic effect of these
peptides. Two distinct PDGF receptors are encoded by two
separate genes. Molecular cloning of mouse and human PDGF
receptor cDNA have shown structural similarity with other
protein tyrosine kinase receptors [11, 42—44]. The two genes
encode two separate receptors, termed alpha and beta receptors
[42—44]. The PDGF A and B chains bind the alpha receptor
subunit, whereas only the PDGF B chain binds the beta
receptor subunit [42]. We recently compared the mitogenic
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Table 4. Hemodynamic effects of growth factors
Growth factor!
Cytokine Hemodynamic effect
PDGF Constricts aortic rings
Contracts mesangial cells, reduces Kf,
increases efferent arteriolar resistance
Dilates certain vascular beds whose
endothelium expresses PDGF
receptors due to release of EDRF
EGF, TGF-alpha Constricts aortic rings
Contracts mesangial cells, constricts
afferent and efferent arterioles, reduces
Kf, decreases renal blood flow and
GFR (rat)
Dilates renal vasculature (dogs)
IGF1 Increases renal blood flow and GFR
bFGF Vasodilates systemic and renal
vasculature due to release of EDRF
IL-i Inhibits contraction of aortic rings; lag
period requires protein synthesis; not
dependent on endothelium
TNF Shock with systemic hypotension
effect of all three isoforms in human mesangial cells; our data
indicate the predominance of beta receptors in mesangial cells
[45]. The mitogenic signals that transduce the effects of PDGF
receptor activation are similar to those reported in other cell
systems, although they have been less extensively studied in
mesangial cells [46]. It is likely that the PDGF beta receptor is
the major target for PDGF in the glomerulus and specifically in
mesangial cells. The PDGF receptors are subject to regulation
by PDGF itself as well as by other peptides [47-49]. Therefore
PDGF, as well as its receptor, might amplify an inflammatory
response to PDGF itself or to other cytokines.
Platelet-derived growth factor also is a chemoattractant for
mesangial cells [50]. This property is likely to be an important
mechanism for intraglomerular migration of mesangial cells
following mesangiolysis or necrosis. PDGF, like other cyto-
kines, has vasoactive properties (Table 4). As a potent vaso-
constrictor [51], PDGF elicits contraction of mesangial cells, a
property that might regulate the ultrafiltration coefficient [52].
Preliminary micropuncture studies in the rat, in which PDGF
was infused into the renal circulation, demonstrated a marked
decrease in renal blood flow and glomerular filtration rate, an
increase in efferent arteriolar resistance, and a fall in the
ultrafiltration coefficient [53]. Infusion of PDGF into the iso-
lated microperfused glomerulus markedly increases intraglo-
merular capillary pressure and is associated with a decrease in
flow rate and a marked increase in vascular resistance (Abboud
H, Osgood R, unpublished observations). PDGF may act as a
vasodilator in certain vascular beds. Vessels with endothelial
cells that express PDGF receptors undergo vasodilation in
response to the BB isoform because of a release of endotheli-
urn-derived relaxing factor [54]. PDGF regulates matrix metab-
olism in mesangial cells either directly or through the release of
other growth factors such as TGFI3 [33, 55, 56]. Although
PDGF does stimulate the production of decoi-in as well as
biglycan, it is less potent than is TGF/3 [55]. Indirect in-vitro
evidence suggests that PDGF mediates the increased expres-
sion of type-TV collagen mRNA in response to advanced
glycosylated end products that accumulate in diabetes [56].
These in-vitro studies provided a major impetus for an explo-
ration of the role of PDGF in vivo.
Evidence is accumulating in humans and experimental ani-
mals that PDGF is heavily involved in inflammatory and prolif-
erative glomerular diseases. An increased expression of PDGF
has been demonstrated histochemically in glomeruli from pa-
tients with lupus nephritis [57]. Immunohistochemical studies
demonstrated that expression of PDGF beta receptor is in-
creased in rejected kidney transplants and in human renal
biopsy specimens obtained from patients with proliferative
glomerulonephritis [58, 59]. Working with our group, Gesualdo
demonstrated an increased expression of PDGF in experimental
animals with proliferative glomerular disease as well as in renal
biopsy tissue obtained from patients with a variety of renal
lesions [60]. In two models of IgA nephropathy induced by the
administration of charged dextran, histochemical techniques
and solution hybridization analysis, respectively, demonstrated
the increased expression of PDGF and PDGF B-chain mRNA in
kidneys from diseased mice; PDGF was localized primarily
within mesangial areas of glomeruli and to a lesser extent in the
interstitium [60]. The increased PDGF expression correlated
with the degree of hypercellularity and clinical features of the
disease. Given that glomeruli occupy less than 5% of renal
mass, the detection of the increase in PDGF mRNA in whole-
kidney tissue and the presence of PDGF in extraglomerular
structures clearly illustrate the contribution of the interstitium
to the expression of PDGF. Potential sources of PDGF in the
interstitium include infiltrating mononuclear cells, vascular
endothelial and smooth muscle cells, tubular epithelial cells
such as inner medullary collecting duct cells [61], and likely
interstitial cells such as fibroblasts. In addition to lupus nephri-
tis, increased expression of PDGF has been demonstrated in
glomeruli from patients with IgA nephropathy and, interest-
ingly, focal glomeruloscierosis but not minimal-chain disease
[62]. lida and colleagues demonstrated a marked increase in the
expression of PDGF B-chain as well as PDGF beta-receptor
mRNA and their translated proteins in glomeruli from a rat
model of proliferative glomerulonephritis [63]. The rats had
severe proliferative lesions induced by anti-thy 1 antibodies.
The increased expression of both PDGF and its receptor
indicate that PDGF probably participates in the pathogenesis of
cellular proliferation of this disease. In-situ hybridization stud-
ies in the same model localized PDGF mRNA transcripts to
mesangial cells [64]. More recently, the same investigators
demonstrated that infusion of antibody to PDGF reduced the
late phase of mesangial cell proliferation by more than 50%
during the course of this disease [65]. Complement depletion or
platelet depletion significantly reduced cell proliferation and
PDGF expression. Additional in-vivo evidence suggesting that
PDGF provokes renal and glomerular injury is provided by
studies in a remnant kidney model in the rat [66]. In this model,
mesangial cell proliferation was documented before the devel-
opment of glomerulosclerosis and was associated with an
increased expression of glomerular PDGF mRNA and protein.
The researchers found proliferation of mesangial cells within 3
to 5 days of renal ablation and, to a lesser degree, of endothelial
cells starting at day 5 and persisting up to 4 weeks. The
increased glomerular cell proliferation was associated with an
increased expression of PDGF B-chain by immunohistochem-
istry. In-situ hybridization revealed the induction of PDGF
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B-chain mRNA between weeks one and four. In addition, the
increased expression of PDGF beta-receptor mRNA and recep-
tor protein was demonstrated by Northern blot analysis and
immunohistochemistry. The onset of glomerular cell prolifera-
tion was associated with mild glomerular platelet accumulation
as well as with fibrin deposition. Proteinuria, glomerular scle-
rosis, and leukocyte infiltration followed cellular proliferation.
These data strongly suggest that PDGF causes mesangial cell
proliferation and possibly contributes to the initiation and
progression of renal injury in this experimental model.
Given its chemotactic and vasoactive properties, PDGF also
is likely to influence other aspects of glomerular pathology
besides proliferation [67]. PDGF can activate neutrophils and
monocytes to release lysosomal enzymes and neutral proteases,
and fibroblasts to release collagenase, thereby influencing tissue
remodeling [67—69]. Shear stress stimulates PDGF expression
[701, thus providing a potential link between hemodynamic and
metabolic mechanisms of glomerular injury.
Transforming growth factor f3
Transforming growth factor f3 is secreted from most cells, and
is released from platelets in an inactive or latent form [71—74].
The latent form of TGF/3 released by human or rat platelets
consists of three distinct components. (1) Mature TGFJ31, the
active component, is a 25 kD molecule comprising two identical
disulfide-linked polypeptide chains. (2) The N-terminal remnant
of the TGFI31 is denoted "TGF/31 latency-associated peptide"
because it is sufficient to confer latency. (3) A novel type of
protein, denoted the "latent TGF/31-binding protein," associ-
ates with the TGF/31 rapidly inside the cells, and this associa-
tion appears important for the proper assembly and secretion of
TGFJ31. A post-translational modification of TGF/31 takes place
before secretion; this modification is distinct from the activation
events required for the generation of biologically active TGFP
from the latent molecule [72]. Given that most cells in culture
release latent TGFP in various forms, and that latent TGF/3
does not bind to the TGFf3 receptor(s), an understanding of the
regulation of the release of the active form and the mechanism
of activation of TGFI3 is crucial for delineating the biologic role
of this peptide [75—77]. Latent TGF/3 can be converted into the
active form by strong acid treatment in vitro. The biologic
relevance of this method of activation is doubtful, however.
Purified latent TGFI3 also can be activated by plasmin. Plasmin
appears to act by cleaving within the amino terminal region of
the TGFp1, thereby destabilizing the latent complex and releas-
ing active TGFI3 [75]. Two recent reports described the conver-
sion of latent TGFI3 to the active species in co-cultures of
endothelial cells and pericytes or smooth muscle cells [76—78].
Pericytes or smooth muscle cells inhibit endothelial cell mitosis
and movement because they form active TGFf3. Activation of
TGF/3 requires cell-cell contact or very close apposition of the
two different cell types. Inhibitors of plasmin block the forma-
tion of active TGFI3. The active TGF/3 produced induces the
synthesis of plasminogen activator inhibitor, which blocks the
subsequent conversion of plasminogen to plasmin and thereby
further suppresses the activation of latent TGF/3 [77]. It is
interesting to note that co-culture of endothelial and mesangial
cells inhibits endothelial cell DNA synthesis, whereas the
addition of medium conditioned by mesangial cells does not
affect endothelial cell DNA synthesis [79]. It is likely that
contact of endothelial and mesangial cells activates TGFI3
released by either cell type. The mechanism of activation of
TGF/3 is probably relevant to the pathogenesis of renal pathol-
ogy; active TGF/3 is released both by cortical tissue and by
isolated glomeruli from several models of proliferative glomer-
ulonephritis, including the anti-thymocyte model and an anti-
glomerular basement membrane model [80, 81]. Gamma inter-
feron and retinoids stimulate macrophages to release active
TGFJ3 [82].
The biologic actions of TGF/3 are diverse [72—85]. In the
main, this factor suppresses cell proliferation and fosters cell
adhesion [72]. These effects are accomplished by enhanced
synthesis and deposition of extracellular matrix components,
decreased proteolysis, and modification of cell-surface-adhe-
sion receptors known as integrins. The integrins in turn control
migration, homing, and settlement during tissue remodeling.
Integrins are one of the best-characterized families of cell-
adhesion receptors [72, 85]. Many integrins function as adhe-
sion receptors for extracellular matrix components such as
fibronectin, collagen, laminin, vitronectin, fibnnogen, von
Willebrand factor, and others. This effect of TGFf3 on extracel-
lular matrices is likely to play a major role in the development,
morphogenesis, tissue repair, and pathogenesis of fibrotic and
sclerotic states in the kidney as well as in other tissues. Further,
TGFf3 elevates the expression of many matrix protein compo-
nents, including fibronectin, type-I collagen, alpha I and alpha
II chains, and collagen types III, V. and VI. Some of these
effects have been demonstrated in mesangial and epithelial cells
[56, 72, 86, 87]. Other matrix glycoproteins in which synthesis
is induced with TGF/3 include osteopontin, osteonectin, tenas-
ci thrombospondine, and the chondroitin dermatan sulfate
proteoglycans known as biglycan and decorin. Induction of
matrix synthesis is a major response observed also following
the in-vivo local injection of TGFI3I in animals. TGF also
inhibits proteolysis of extracellular matrix. In mesangial cells,
plasminogen activator inhibitor 1 and tissue inhibitor of metal-
loprotease, two inhibitors of extracellular matrix-degrading
enzymes, also are strongly upregulated by TGFf3. One study
also reported that TGF/3 decreases the expression of collage-
nase, stromelysin, plasminogen activator, and certain proteases
[72].
The cellular mechanisms of action of TGF/3 are unknown
despite a great deal of study over the past decade. None of the
pathways for intracellular signaling, including phospholipid
turnover, modulation of intracellular cyclic AMP level, and
tyrosine phosphorylation, has been directly linked to TGF/3
action [72]. The likely candidates are three cell-surface proteins
that have been identified through their ability to bind and be
chemically cross-linked to radioiodinated TGF/3. They are
termed type I, type II, and type III receptors, and have
molecular weights of 55, 88, and 280 kD respectively. The
TGF/3 type II and type III receptors recently were cloned and
are likely to clarify signal transduction mechanisms involved in
the action of TGFJ3 [88].
Since TGFf3 is stored in high concentrations in platelets [72]
and is expressed in activated monocytes and macrophages
found within the kidney [72, 89], it is likely to be a major factor
in inflammatory diseases of the kidney. In this setting, TGF3 is
likely a promoter of extracellular matrix deposition and proba-
bly regulates cell migration and development. Also, TGFI3 is an
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extremely potent chemoattractant for monocytes, and to a
lesser extent fibroblasts, and therefore might attract these cells
to sites of inflammation and repair in the kidney. Excellent
experimental evidence indicates that TGF/3 plays an important
role in mediating some of the pathologic changes observed in
the kidney [83, 90—95]. High levels of TGFf31 mRNA and
protein are expressed in glomeruli as compared with whole-
kidney tissue [90, 91]. TGFI32 mRNA, on the other hand, is
present only in glomeruli and is not detected in whole kidney.
Binding proteins (receptors) in rat glomeruli are unique and
differ from those described in cultured cells in their affinities to
the various forms of TGFI3 [91, 92]. Although the function of
these binding proteins remains to be defined, they might store
TGF/3 and therefore regulate its bioavailabiity.
Immunohistochemical distribution of TGF/31 does not always
match the distribution of the corresponding mRNA, and this
discrepancy could reflect (1) diffusion and accumulation of the
protein away from its site of synthesis, (2) a lack of translation
of the mRNA, or (3) immune cross-reactivity with other forms
of TGF/3. Freshly isolated glomeruli and glomerular cells in
culture, including mesangial, epithelial, and endothelial cells,
express receptors for TGFf3 [861.
In general, TGFf3 is a potent inhibitor of glomerular cell
proliferation including mesangial, endothelial, and epithelial
cells [25, 86]. The effect of TGF/3 on cell proliferation is
influenced by several factors including the target cell, the
presence of other cytokines, the type of matrix, and the cell
density. For example, mesangial cells plated at high density
respond in a positive fashion to TGFf3 [86]. The inhibitory effect
of TGFI3 is markedly attenuated when cells are plated at high
density and allowed to grow in the presence of serum (personal
observations). Whether these in-vitro events are relevant in
vivo remains to be determined. TGFJ3 also stimulates matrix
production both in mesangial and epithelial cells [56, 83, 86, 87].
It significantly increases the production of collagen and fi-
bronectin by glomerular mesangial cells, but only fibronectin
production is augmented in glomerular epithelial cells in re-
sponse to TGFI3. In addition, TGF/3 increases the production of
biglycan and decorin, and stimulates the deposition of fibronec-
tin on the mesangial cell surface [56, 83, 87].
These in-vitro observations prompted in-vivo studies indicat-
ing that TGFp contributes to the mesangial matrix expansion
that occurs in glomerular disease [92—95]. Okuda et al demon-
strated increased expression of TGF/3 mRNA and de-novo
synthesis of TGF/3 protein in glomeruli from an experimental
rat model of glomerulonephntis induced by injection of anti-
thymocyte serum [931. In this model, mesangial expansion
coincided with elevated proteoglycans synthesis and the secre-
tion of active TGFI3 by glomeruli. More recently the same
group of investigators demonstrated amelioration of matrix
expansion in glomeruli after treatment of the diseased rats with
antibody to TGF/3 [94]. Most recently, dietary maneuvers such
as protein restriction reduced both matrix expansion and TGFJ3
expression in the same model [95]. Further, TGFJ3 might
promote the glomerular pathology observed in anti-glomerular
basement membrane disease in the rabbit [81]. Cortical tissue
from diseased kidneys releases active TGFI3 into conditioned
medium that, in turn, stimulates collagen synthesis in cultured
rabbit mesangial cells, The secretion of TGFJ3 is accompanied
by an increase in renal cortical TGFI3 mRNA content. Isolated
TGF-beta
Proliferation Fibrosis
Fig. 1. Schematic depiction of the role of cytokines in proliferation and
fibrosis
glomeruli from diseased animals release active TGFf3; isolated
glomeruli from control animals release latent TGF/3. The in-
creased release of TGF/3 was accompanied by an increased
expression of TGF/3 mRNA [811. We recently demonstrated
that cultured mesangial cells release latent TGF/3 constitutively
[33]. In addition, PDGF and EGF stimulate the release of latent
TGF/3 and stimulate the expression of TGFI3 mRNA [33]. Data
from these studies and in-vivo studies that compared the effects
of PDGF and TGF/3 infused subcutaneously [96, 97] led us to
believe that the relative expression of PDGF and EGF, taken
together with the activation of TGFJ3, probably determines the
nature and progression of the inflammatory lesion in glomeruli.
Expression of PDGF or EGF, as well as other positive growth
regulators initially, might result in increased cell proliferation.
However, as the lesion progresses, the activation and enhanced
TGF/3 production acting on mesangial cells, or other cells that
may invade the glomerulus, such as fibroblasts, increase the
synthesis of matrix components and eventually cause fibrosis.
Thus, the differential expression of these peptide growth factors
might determine the ultimate outcome of the glomerular lesion,
proliferation, or fibrosis (Fig. 1).
TGFI3 is a potent negative and positive modulator of the
immune system. The antiproliferative action of TGF on
B-lymphocytes, T-lymphocytes, and thymocytes is among the
immunosuppressive activities displayed by this factor in vitro
and in vivo [98, 99]. Like cyclosporine, TGF/3 inhibits the
release of several cytokines, including 'y-interferon, and TNF/3,
from peripheral blood mononuclear cells and tissue macro-
phages [99]. Since mononuclear infiltration is a prominent
histologic feature both in glomeruli and interstitium during
many forms of glomerulonephritis, TGF/3 might act as an
endogenous immunosuppressive agent at some stage of renal
injury.
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Interleukin-6
Interleukin-6 (IL-6) is another cytokine that might be in-
volved in proliferative glomerular diseases [100, 101]. A 26 kD
protein originally identified in the culture supernatants of stim-
ulated peripheral mononuclear cells, IL-6 is produced by B- and
T-lymphocytes, endothelial cells, fibroblasts, and epithelial
cells. Whole-kidney tissue expresses IL-6 mRNA. Horii et al
first demonstrated that cultured rat mesangial cells release
biologically active IL-6 and express IL-6 mRNA as determined
by Northern blotting and in-situ hybridization [102]. Moreover,
the same investigators demonstrated that IL-6 induces DNA
synthesis in rat mesangial cells in the presence of fetal calf
serum. Coleman, Reuf, and colleagues also demonstrated that
rat mesangial cells release IL-6 and express IL-6 mRNA [101,
103]. Physicochemical characterization of mesangial cell IL-6
demonstrated similarity to IL-6 from other sources. Rat mesan-
gial cells also respond to IL-6 in the presence of a low
concentration of fetal calf serum. Several factors stimulate IL-6
release from rat mesangial cells; these factors include PDGF-l,
IL-6, fetal calf serum, lipopolysaccharide, and TNFa [101,
104]. In fibroblasts, glucocorticoids inhibit IL-6 production.
Certain matrix components, such as collagen type I, also inhibit
IL-6 release in mesangial cells in a dose-dependent fashion.
More definitive evidence for the potential role of IL-6 in
glomerulonephntis comes from the demonstration that overex-
pression of IL-6 in mice transgenic for this cytokine results in
mesangial proliferative glomerulonephritis [105].
Utilizing a monoclonal antibody to IL-6, Hon and colleagues
localized the cytokine to mesangial cells in biopsy specimens
from patients with proliferative glomerulonephritis, but not
from patients with membranous nephropathy, minimal-change
disease, or normal tissue [102]. Other studies also have dem-
onstrated that the expression of IL-6 by immunofluorescence
techniques correlates with an increase in glomerular cell num-
ber in patients with proliferative glomerulonephritis [106]. The
precise cellular origin of IL-6 remains to be determined, how-
ever. Urine from patients with proliferative glomerulonephntis,
but not from patients with minimal-change or membranous
nephropathy, also contains large amounts of IL-6. One study
demonstrated a positive correlation between the urinary level of
IL-6 and the severity of the proliferative lesions [102, 106].
Glomerular tissue from patients with advanced sclerosis dem-
onstrates reduced binding of IL-6 [102, 106]. A definitive role
for IL-6 in inducing proliferative glomerular diseases awaits
further studies demonstrating that the administration of IL-6
receptor antagonists or an antibody to the protein or its receptor
attenuates or blocks the proliferative process in the glomerulus.
Interleukin-1, TNF, and y-interferon
The role of cytokines in general, and of these three cytokines
in particular, in glomerulonephritis was reviewed recently [16].
Evidence suggests that these cytokines are involved in the
initiation stage or in perpetuating certain forms of immune-
mediated renal injury. Most of the pioneering work on cyto-
kines and mesangial cell biology focused on the role of IL-i
[107—109]. Human and rat mesangial cells synthesize IL-i and
express IL-la and IL-1/3 mRNA transcripts. Serum, PDGF,
and EGF stimulate IL-i production in mesangial cells [108].
TNFa is synthesized by mesangial cells, and its synthesis is
stimulated by lipopolysaccharide and inhibited by prostaglandin
E2 and cAMP [110, 111]. IL-l, TNF, and y-IFN exert several
biologic activities in mesangial cells, all of which are relevant to
the pathologic manifestations of giomerular and interstitial
involvement in glomerulonephritis [16]. Effects elicited by IL-i
in mesangial cells include DNA synthesis, release of proteases,
and collagen synthesis [107, 109]. TNF also activates mesangial
cells to release procoagulant activity, plasminogen activator,
and plasminogen activator inhibitor [111]. TNF and y-interferon
also induced expression of MHC-I and -II in mesangial cells
[16]. Increased expression of TNF and IL-i have been demon-
strated in vivo in several animal models of glomerulonephritis
[112—115]. Increased IL-l/3 mRNA has been demonstrated in
membranous nephropathy [112], IgA nephropathy [16], and
puromycin aminonucleoside nephrosis in the rat [116]. In mu-
nne lupus models, that is, MRL lpr/lpr, and NZB/NZWFI,
expression of mRNA encoding IL-lp and TNF is increased in
renal cortex and isolated glomeruli as compared with levels in
control mice (that is, MRL) [113—115]. Glomerular cultures
from patients with rapidly progressive glomerulonephritis also
release IL-i activity [117, 118]. Of interest is the finding that
some cytokines worsen the manifestations of immune-mediated
renal injury. The administration of IL-i or TNF potentiates
renal injury in murine lupus models, anti-GBM antibody dis-
ease, and IgA nephropathy. Lipopolysaccharide, when admin-
istered with subnephritogenic doses of anti-GBM antibody,
increases IL-i production by glomeruli, potentiates proteinuria,
and worsens histologic abnormalities [119]. IL-lp and TNF had
similar effects [16, 120]. Infiltrating inflammatory cells appear to
be the major cellular source of cytokines in these models [116].
Other cytokines synthesized by mesangial cells include mac-
rophage colony-stimulating factor, granulocyte-macrophage
colony-stimulating factor (GM-CSF), and interleukin-8, a neu-
trophil-chemotactic peptide [16]. ILa, IL-113, TNF, and lipo-
polysaccharide stimulate the release of IL-8 [121, 122]. The
synthesis of colony-stimulating factor 1 also is stimulated by
y-interferon and is inhibited by dibutyryl cAMP [123].
Insulin-like growth factor-I
No studies exploring the role of IGF1 in immune-mediated
glomerulonephritis are available as yet. However, evidence
does exist that overexpression of IGF-1 contributes to the
progression of glomerular injury [l24—126]. Renal, and specifi-
cally glomerular, hypertrophy has been incriminated as a risk
factor for the progression of renal disease in patients and
experimental animals following significant loss of renal mass,
irrespective of the primary renal disease [4, 5, 10]. Some
investigators have suggested that hypertrophy, even without
loss of renal mass, is a prerequisite for mesangial expansion and
sclerosis of the glomerular microvascular bed [4, 5, 7, 10].
Peptide growth factors might be involved in glomerular hyper-
trophy, as has been suggested for 1GF1 [124—126]. Recent
studies utilizing mice transgenic for growth hormone (GH),
growth-hormone-releasing factor (GHRF), and IGF1 demon-
strated that only mice transgenic for GH and GHRF develop
hypertrophy and sclerosis [126]. Mice transgenic for IGF1 did
develop some hypertrophy but little sclerosis, even though
circulating levels of IGF1 in the animals transgenic for IGF1
were higher than in those transgenic for GH and GHRF.
Glomerular levels of IGF1 were not reported, however, and
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local release of IGF1 might have been responsible for the
hypertrophy [124—126]. Alternatively, additional growth factors
other than IGF might mediate the effect of GH. Of particular
interest in these studies was the disproportionate hypertrophy
of glomeruli compared with total-kidney or total-body weight of
the animals. A potential interesting role for IGF1 in mediating
the increased renal blood flow and glomerular filtration rate in
remnant nephrons is suggested by the observation that infusion
of IGF in fasting rats increases renal blood flow and glomerular
filtration rate [127, 128].
Additional evidence suggests that IGF1 is involved in the
pathogenesis of diabetic nephropathy. Mesangial cells from
genetically diabetic mice, db/db, express higher levels of IGF1
receptors than do mesangial cells from control db/m mice [129].
Both IGF1 and insulin receptor mRNA expression were in-
creased in db/db mesangial cells grown in the presence of
high-glucose medium. Abnormalities in IGF1 receptor regula-
tion in this as well as other models of glomerular injury should
be explored. In-vitro studies showed that glomerular mesangial,
epithelial, and endothelial cells produce IGF1 and IGF1-binding
proteins. IGF1 binds to specific receptors in these cells and
stimulates DNA synthesis [130—133]. Moreover, IGF1 is re-
leased from monocytic cell lines and from macrophages [134].
These studies suggest a potential role for IGF1 as a mediator of
matrix expansion and hypercellularity in glomerulonephritis.
Cytokines and inflammatory cells
Circulating inflammatory cells might be a target for immune
processes that initiate and propagate renal injury in glomerulo-
nephritis. In some diseases, such as lupus nephritis and IgA
nephropathy, evidence exists for activation of the various
mononuclear cell types including monocytes, T- and B-lympho-
cytes, and platelets [135]. Such activation may result in the
release of several cytokines either into the circulation or locally
in the kidney, or into specialized tissue such as lymphoid
organs, where cell proliferation and phenotypic modulation of
these cells can occur. Increased expression and release of these
cytokines probably affects the severity of the renal lesions. It is
very unlikely that PDGF or TGF/3 secreted by circulating
mononuclear cells would be readily accessible to the glomeru-
lus, interstitium, or even blood vessel wall, since these cyto-
kines would be rapidly inactivated in the circulation by com-
plexing with plasma proteins. However, IGF1, IL-i, IL-6, and
TNF are some of the cytokines that probably gain access to
target organs not only through autocrine or paracrine pathways
but also through the systemic circulation [136]. Mononuclear
cells that are trapped in an inflammatory lesion within the
glomerular microvascular bed or the interstitium may be in
direct contact with each other and with glomerular or interstitial
cells. Monocyte entry and macrophage exit from renal lesions
might be a continuous and direct process, as has been demon-
strated in experimentally induced atherosclerotic lesions [137].
The possibility therefore exists that circulating mononuclear
cells are activated during their journey in the glomerular micro-
vascular bed and interstitium and result in the local release of
PDGF, TGF/3, or other cytokines. Such a scenario is consistent
with observations of a positive correlation between PDGF
B-chain expression in peripheral blood mononuclear cells and
histopathologic changes and urinary protein excretion in a
recent study of IgA nephropathy [138, 139]. The demonstration
of an increased expression of these cytokines in monocytes,
macrophages, or lymphocytes infiltrating renal tissue would
provide more direct evidence for a role for mononuclear cells in
glomerular and interstitial lesions. In this setting, it is likely that
monocytes and macrophages as well as T-cells interact with
each other and with intrinsic glomerular or interstitial cells.
This interaction leads to the release of multiple cytokines that
result in cell proliferation, matrix expansion, and eventual
fibrosis.
Conclusion
The interest in cytokines as regulators of cultured glomerular
cells has grown rapidly and now includes active exploration of
the role of cytokines in glomerular injury in vivo. Their role in
mediating interstitial changes, which invariably accompany
glomerular disease, is less well researched but currently is being
explored. The availability of recombinant cytokines, neutraliz-
ing antibodies, and receptor antagonists should facilitate studies
exploring the role of cytokines in mediating renal injury in
experimental models of glomerulonephritis and other models of
glomerular injury. Detailed chronologic studies in experimental
animals might establish a cascade of events specific for certain
mechanisms of injury. In addition, such studies will help
establish temporal relationships between cytokine expression,
inflammatory cell infiltration, cell proliferation, matrix expan-
sion, and changes in renal function. Logistic difficulties will be
encountered in assessing the role of cytokines in human sub-
jects. However, a concerted application of techniques such as
immunohistochemical staining and in-situ hybridization to renal
biopsy specimens from patients with different diseases is likely
to advance our understanding of cytokine involvement in
human renal pathology very quickly. The results of such studies
also might bring us a greater understanding of the mechanisms
of renal injury; we might even be forced to redefine what
constitutes an active lesion warranting continuous treatment.
The expression in a renal biopsy specimen of certain pheno-
typic markers denoting cell activation (for example, a cytokine,
or an intermediate filament such as alpha smooth muscle actin)
may well turn out to be a more sensitive index of disease
activity than is a simple assessment of cellularity or crescent
formation. The participation of other inflammatory cells, such
as eosinophils and mast cells, remains unexplored. There might
be therapeutic implications for cytokine expression in intrinsic
glomerular cells versus infiltrating inflammatory cells. An initial
regimen of immunosuppression could be followed by mainte-
nance courses of less toxic agents that result in the "deactiva-
tion" of mononuclear cells and thereby decrease expression of
cytokines. Identifying potential inhibitors of glomerular cell
proliferation and cytokine release or action in vitro might have
important applications in vivo. These agents also might improve
glomerular pathology by a direct inhibitory effect on mesangial
cells as well as inhibition of growth factor release from plate-
lets, monocytes, or lymphocytes. I believe there is a good
rationale for suppressing the immune system and at the same
time attempting to inhibit glomerular and interstitial cell activa-
tion, proliferation, and matrix expansion. It makes perfect
sense to use chronic regimens of less toxic drugs that can inhibit
or deactivate intrinsic glomerular cells as well as the remaining
infiltrating inflammatory cells, and thereby prevent the devel-
opment of otherwise progressive renal failure.
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Questions and answers
Du. F. PAOLO SCHENA (Chief of Nephrology, University of
Ban, Ban, Italy): Circulating immune complexes, or "in-situ"
formed immune complexes, activate the complement system at
the glomerular level. Over the last few years, investigators have
demonstrated the presence of some complement components,
such as CSb-9, in the active phase of some glomerulonephritides
(lupus nephritis, IgA nephropathy, and membranous nephrop-
athy) [140—142]. Moreover, other investigators recently have
shown that C5b-9 induces cytokine production in cultured
mesangial cells [143]. Is there a correlation between the com-
plement system and growth factors?
DR. ABBOUD: Lovett et al first reported that C5b-9 membrane
attack complex stimulates IL-i production in mesangial cells
[1441. The study you are citing demonstrated that C5b-9 stim-
ulated the synthesis of IL-i, IL-6, and TNF by mesangial cells
[143]. Immune complexes acting through Fc receptors, how-
ever, can directly activate mesangial cells to release cytokines,
specifically colony-stimulating factor (CSF-l) and monocyte-
specific chemoattractant protein (MCP-l); this effect was dem-
onstrated recently by Hora et al [1451.
DR. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York, USA):
You stated that in only a few instances thus far has inhibition of
a cytokine been shown to retard the development of disease. In
the absence of more data, how confident can we be that the
mere presence of a given cytokine in the tissue, or even of the
mRNA for a given cytokine, has pathogenetic significance,
given the welter of these cytokines that are present?
DR. ABBOUD: It is true that the association of overexpression
or underexpression of a particular cytokine with a renal lesion
does not necessarily establish a pathogenetic role. To establish
a cause-and-effect relationship, one has to rely on antibody or
receptor antagonist studies and demonstrate that neutralizing
the biologic effect of the cytokine ameliorates or abolishes the
structural or functional consequence of a disease process.
Neutralizing antibodies for TGF-/3 and PDGF recently have
been utilized to establish the role of these two cytokines in
mesangial cell proliferation and matrix expansion in a rat model
of acute proliferative glomerulonephritis [65, 94]. Changes in
the expression of a cytokine, however, might be helpful as a
diagnostic tool for determining the state of activation or differ-
entiation of infiltrating inflammatory cells or intrinsic glomeru-
tar cells. Most inflammatory cells express cytokines only when
they are activated [27]. Expression of cytokines by intrinsic
glomerular cells also might be a sign of activation.
DR. R. BERNDT STERZEL (Professor of Medicine, University
of Erlangen-Nflrnberg, Germany): I am concerned about how
cytokines might be influenced by the variable degree of sclero-
sis present in these glomerular diseases. It seems to me that
sclerosis itself might affect the presence of cytokines in at least
two ways. One, cytokines might be sequestered passively in the
sclerotic material, and two, the matrix material in the sclerotic
areas might modulate the phenotype of the mesangial cell,
altering PDGF expression.
DR. ABBOUD: This is an important issue that I would like to
discuss further. Changes in the amount, nature, and composi-
tion of matrix can have profound effects on mesangial cell
behavior [18, 85, 146]. There is a continuous and dynamic
process of communication between matrix and cell-surface
receptors. Matrix components also facilitate cell-to-cell com-
munication. Certain cytokines, such as TGF-/3 or basic fibro-
blast growth factor, bind to matrix and are released slowly,
thereby influencing the surrounding cellular elements. There-
fore, one mechanism by which extracellular matrix material
might influence behavior of cells is via sequestration and
subsequent release of cytokines. This process could be regu-
lated by inflammatory mediators [147].
Extracellular matrix could modulate mesangiai cell behavior
by additional mechanisms. Specific receptors for matrix pro-
teins are present on most cells. For example, receptors for the
integrin family of adhesion molecules are present on glomerular
cells and may mediate the binding of matrix proteins such as
laminins, collagens, and fibronectin [18]. Matrix protein might
influence growth and differentiation of cells as well as expres-
sion of cytokines and/or cytokine receptors. Matrix modulates
the release of IL-6, the expression of PDGF receptors, and the
synthesis of collagen by mesangial cells [18]. This area deserves
more exploration in vitro as well as in vivo. Particularly
relevant is the identification of the effect of the matrix on
glomerular cells in vivo. For example, what is the interaction
between matrix components and glomerular cells in patients
with a moderate degree of sclerosis? Studies in experimental
models of progressive glomerular disease provide evidence for
the presence of activated and proliferating cells around such
lesions, even when total cellularity is decreased [148]. This
observation raises questions about the traditional interpretation
of human renal biopsies and about our current ability to
distinguish between active disease, on the one hand, and
chronic and/or inactive disease, on the other. I believe that
special techniques should be applied to identify markers for
disease activity such as the expression of intermediate filaments
or cytokines [149]. Cytokines have diverse and occasionally
opposite biologic effects. Therefore, different cytokines can be
expressed at different stages of a disease process.
DR. COHEN: Dr. Striker, would you like to comment?
DR. GARY STRIKER (Director, Division of Kidney, Urologic,
and Hematologic Diseases, National Institutes of Health,
Bethesda, Maryland, USA): A couple of findings have turned
out to be a major surprise for us. One is that examination of
histologic sections is not sufficient to determine proliferation.
We are reasonably good at counting dots, but that gives us no
idea about cell turnover; proliferation must be assessed directly
[148]. I agree with Dr. Sterzel that the kind of matrix that one
finds needs to be defined more carefully. Pathologists can stain
tissue with PAS, but that method doesn't tell us much about the
amount, type, or mixture of various matrix components, all of
which are likely to be very important. I am very impressed, Dr.
Abboud, with your notion of a rheostat—of up-regulating one
and down-regulating another. I agree that the balance of growth
factors will be very important. Finally, I believe we have to
stage these complex processes carefully. Antibody studies
alone might be misleading; for example, TGF-/3 at one stage is
probably quite important, as you've shown, whereas PDGF
might be important at a later stage.
DR. LORETO GESUALDO (Clinical Fellow, Division of Nephrol-
ogy, University of Ban): I've been interested in the expression
of PDGF mRNA in renal biopsies [6]. We have been unable to
Nephrology Forum: Growth factors in glomerulonephritis 261
find an increased expression of PDGF mRNA in IgA nephrop-
athy during the GS stage (that is, end-stage renal disease), but
we do find it during stages 03 and 04. So maybe Dr. Sterzel's
suggestion is correct: PDGF might merely bind to the matrix at
late stages and thereby become detectable by immunoperoxi-
dase staining, but its presence might have no pathogenetic
significance. I believe, however, that in the early stages of the
disease, PDGF alone or in combination with other growth
factors could play an important pathogenetic role.
I have a question: since cAMP analogues can reduce prolif-
eration, when do you think therapy should be started with such
analogues? IgA nephropathy is a chronic disease. Patients
usually do not develop renal insufficiency until the disease has
been present for many years. Do we have to begin treatment
early, or should we wait until renal insufficiency begins to
develop?
DR. ABBOUD: Let me address the first point you raised
regarding cytokine localization by immune peroxidase tech-
niques and/or localizing the mRNA by in-situ hybridization. If
at an early stage of disease immunoperoxidase or immunofluo-
rescence staining shows that PDGF protein is present, yet
in-situ hybridization fails to disclose that mRNA is expressed or
up-regulated, one should consider the platelet as a source of the
PDGF; platelets have very little machinery for synthesizing
proteins and therefore might merely release PDGF and deposit
it in extracellular sites. If, by contrast, one finds that PDGF
mRNA is expressed and up-regulated, it is likely that macro-
phages or mesangial or endothelial cells are the sources of
PDGF. In advanced stages, the failure to demonstrate PDGF
mRNA expression might be due to the presence of very few
activated glomerular cells or macrophages. In advanced acellu-
lar lesions, obviously one does not expect to detect mRNA.
With respect to treatment using cAMP analogues or adeny-
late cyclase agonists, I certainly believe that this approach
should be considered seriously. The limitation of a protracted
course of immunosuppressive drugs is obvious. Prostaglandin
analogues that activate adenylate cyclase are potential thera-
peutic agents. We and others find that prostaglandins inhibit
mesangial cell proliferation in vitro. Studies in experimental
animals also demonstrated therapeutic benefit in glomerulone-
phritis [1501. The administration of drugs that can deactivate
cells and inhibit cell proliferation may have a "sparing effect,"
permitting the use of lower doses of immunosuppressive ther-
apy. Compounds that decrease platelet aggregation, which also
happen to elevate cAMP levels, deserve further trials because
they might be effective in some patients with proliferative
glomerular diseases, including those with IgA nephropathy
[1301.
DR. LEON G. FINE (Professor and Head, Department of
Medicine, University College and Middlesex School of Medi-
cine, UK): Your discussion focused primarily on the glomeru-
lus. The patient under discussion had progressive renal disease
that was accompanied by extensive interstitial fibrosis and
tubular atrophy. As we know, many pathologists with vast
experience would argue that what one sees in the glomerulus in
progressive renal disease has little to do with whether the
disease will progress. Extensive studies by Professor Bohle and
colleagues revealed that changes in the tubulointerstitial com-
partment appear to reflect the progressive nature of the disease
better than the glomerular changes do [1511. Why is this the
case? I would suggest that the same growth-factor-related
damage that you're describing for the glomerulus also could
affect peritubular capillaries. It is now known, for instance, that
PDGF is produced by some tubular cells—certainly the cells of
the collecting duct [61]. I find it very interesting that the
fibroblast of the renal interstitium, with its regional responsive-
ness to PDGF, indicates that paracrine growth systems likely
are present in the interstitium. Johnson and colleagues have
studied glomerular injury and have shown nicely that tubular
expression of PDGF also is present [641. It's entirely possible,
therefore, that the progressive obliterative vascular injury that
occurs in the interstitium is in fact mediated by a tubular lesion
that is possibly ischemic and which leads not only to the tubular
atrophy, but to the release of growth factors. Finally, this
release of growth factors sets up a fibrotic response in the
interstitium, further aggravating the vascular destruction.
Maybe that's the reason these diseases progress. This is clearly
only a hypothesis at the moment, but we cannot ignore this
possibility when considering the relationship between growth
factors and the progression of renal disease.
DR. ABB0uD: I did not discuss interstitial damage in detail,
not because it is unimportant; the interstitium obviously is very
important, and the careful studies that are now being reported
by several groups, including yours, have emphasized the po-
tential role of the interstitium in progressive glomerular injury
[9]. In some forms of IgA nephropathy, for example, mononu-
clear cells are present in the interstitium [138]. Mononuclear
cells infiltrate glomeruli only in crescentic lesions. The intersti-
tium undoubtedly affects the glomerulus, and vice-versa. The
blood supply to the interstitium passes through the glomerulus.
Both units are therefore interdependent, and a primary injury to
one segment can have a major influence on the other. More-
over, many pathologic processes often target both segments.
DR. LILIANE STRIKER (Senior Investigator, National Insti-
tute of Diabetes and Digestive and Kidney Disease, National
Institutes of Health): I think it's a very exciting time for
investigators in this field, and I'm very grateful to Dr. Abboud
for emphasizing the role of growth factors. For the first time, we
are seeing that we can measure proliferation as, for example,
Johnson's group has done, using antibodies to cyclin (PCNA)
[65]. I'm hoping for a time when we'll be able to analyze biopsy
tissue from a patient with IgA nephropathy, for instance, and
say that the patient has this many attomoles of type-l collagen,
and this many attomoles of PDGF. Therefore, let's start treat-
ment with antisense, for instance, to get rid of the PDGF, or the
TGF-f3, or the IL-6. I think we are heading towards an era when
we are going to be able to produce very specific responses. I
would like Emmanuel Peten to comment because he has devel-
oped in our laboratory a technique using microdissection com-
bined with competitive polymerase chain reaction (PCR) that I
believe holds great promise for quantitating such substances in
individual glomeruli or, for that matter, in the interstitium or
tubular cells as well.
DR. EMMANUEL PETEN (Postdoctoral Research Fellow, Na-
tional Institutes of Health): With the new technique of compet-
itive PCR applied to microdissected human glomeruli, we have
for the first time a quantitative way of assessing specific
molecular events in sclerotic glomeruli [152]. Competitive PCR,
as opposed to standard PCR, is a very sensitive way of
reproducibly quantitating absolute amounts of mRNAs in very
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small samples, that is, in microdissected glomeruli. All the
variables that affect a standard PCR reaction, and that have
hampered its use as a quantitative method, are controlled in
competitive PCR. The basic principle is that the molecule to be
quantitated is co-amplified with an essentially identical syn-
thetic cDNA that will compete with the test cDNA on an
equimolar basis. The level of detectability routinely achieved in
the laboratory is in the l0 attomole range (1 attomole equals
iO'8 mole)! As Dr. Abboud just pointed out, assessing mRNA
expression of some of the multiple growth factors and of some
of the extracellular matrix proteins yields only a partial view
and is short-sighted. Instead, we have to try to integrate the
various growth factors suspected of playing a role in glomerular
diseases into more global schemes and, in the case of the
glomerular extracellular matrix, investigate whether both ma-
trix synthesis and degradation are involved. Such studies uti-
lizing the new tools of molecular biology hopefully will allow us
to predict more precisely the outcome of a glomerular disease in
a patient by basing such predictions on the level of gene
expression in the glomeruli.
DR. COHEN: Is the amount of the renal tissue that we are now
obtaining by routine biopsy procedures sufficient to perform
these kinds of studies?
DR. PETEN: At present, to quantitate one single mRNA
species in a human biopsy specimen with quantitative PCR
requires as little as 0.6 of a glomerulus. For example, with a
human biopsy sample containing 30 glomeruli, the pathologist
could use one half of the tissue to make a diagnosis and could
use the other half for quantitative PCR assay. With that much
material, it is possible to quantitate in absolute terms at least 15
mRNA molecules. We can do a lot with very little tissue. In the
near future, we might even be able to use less material; for
example, of a glomerulus might be sufficient to quantitate
some mRNA species by competitive PCR.
DR. COHEN: Let me ask Dr. Striker about her futuristic
speculation. How might one deliver antisense molecules to be
sure they get to the right place?
DR. STRIKER: You'll have to ask a molecular biologist. It's
my hope that this will be achieved. For now, we are just trying
to describe what happens in human diseases and hoping that, in
the future, some investigators will figure out how to manipulate
the system therapeutically.
DR. NAPIER THOMSON (Monash Medical Centre, Melbourne,
Australia): I would like to play the devil's advocate. You
stressed the potential damaging effect of various growth factors
on the glomerulus. Might some growth factors not have bene-
ficial effects? After all, it's a whole soup, isn't it? We're not
talking about a single element acting at a single time.
DR. STEWART CAMERON (Professor of Renal Medicine,
Guy's Hospital, London, England): I was just going to raise the
same question. For example, you mentioned the very intrigu-
ing, and to me inexplicable, studies by McDevitt, who gave
TNF to mice with lupus and made them better [153]. A lot of
evidence now exists that a T-dependent, murine model of
immune injury—allergic encephalomyelitis—is ameliorated by
TGF-j3 [154, 1551. Would you like to comment on these obser-
vations?
DR. ABBOUD: These are very important and pertinent ques-
tions. Certainly growth factors or cytokines can have beneficial
effects. I do not believe that we should classify cytokines as
"good" or "bad." There is tissue specificity in terms of the
biologic role of cytokines. More important, within the same
tissue and for a given disease entity, it is likely that a given
cytokine can play both a beneficial and a deleterious role,
depending on the timing of up- or down-regulation of either the
cytokine itself or its receptor. For example, PDGF is an
important mediator of mesangial cell proliferation in vitro and in
vivo. Although mesangial cell proliferation and hypercellularity
generally are features of glomerular pathology, the mesangial
cell migration and proliferation that follow mesangiolysis could
represent a beneficial effect of PDGF, helping to repopulate and
restore the cellular architecture of the glomerulus. Similar roles
have been postulated for EGF in tubular epithelial cell regen-
eration after acute tubular necrosis [12]. TGF-13 is another
protein that elicits cellular responses of opposing nature; it can
elicit both immunostimulatory and immunosuppressive effects
in vitro as well as in vivo [98, 99], albeit its immunosuppressive
effects are more widespread. These latter effects include in-
vitro inhibition of cytokine production, T- and B-cell prolifera-
tion, and the expression of DR antigens and Fc receptors on
human lymphocytes. With regard to macrophage functions,
TGF-/3 is basically an antiinflammatory molecule that can
deactivate macrophages in vitro by reducing their production of
cytokines and H202 and by reducing their cytotoxicity. These
in-vitro data provided the rationale for the in-vivo studies that
you referred to, Dr. Cameron; as you noted, these studies
demonstrated a protective effect of TGF-p in experimental
autoimmune encephalomyelitis, as well as in acute and chronic
arthritis in experimental animals [98].
DR. ARTURO BORSATTI (Professor of Nephrology, and Direc-
tor, Division of Nephrology, University Hospital of Padova,
Padova, Italy): In reviewing the factors controlling mesangial
cell growth, you did not mention nitric oxide. I understand that,
strictly speaking, nitric oxide is not a growth factor, but it has
been shown to retard mesangial cell proliferation [156]. Acti-
vated macrophages can synthesize a tremendous amount of
nitric oxide [157]. Accordingly, couldn't infiltration by macro-
phages be considered potentially beneficial rather than delete-
rious?
DR. ABBOUD: Indeed, nitric oxide and cyclic GMP have been
shown to inhibit proliferation both of mesangial cells and
smooth muscle cells in vitro. Macrophages do release large
amounts of nitric oxide. What I am not sure about is whether
"activation" of mononuclear cells entails a generalized mech-
anism in which the cells release growth factors and nitric oxide
simultaneously, or a selective mechanism in which the cells
release some but not all macrophage products. Again, whether
infiltrating macrophages play a beneficial or a deleterious role
likely depends on the stage and nature of the pathologic lesion.
DR. VIcKI E. RUBIN-KELLY (Associate Professor of Medi-
cine, Harvard Medical School, Boston, Massachusetts): I
would like to make two comments. The first has to do with the
administration of cytokines. I think the dose is critical. Dr.
McDevitt's group used extremely high doses of TNF and found
improvement not only in animals with lupus [153] but in
non-obese diabetic mice as well [158]. Large doses of IL-i also
can retard disease. Since we reported increases in TNF and
IL-l in lupus nephritis [113], we examined the issue by looking
at a wide range of doses and found that lower levels of
cytokines produced a more physiologic level and, when given at
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a certain point in the disease, accelerated the disease process
[115]. I think large doses of TNF, in particular, probably act
directly by elevating cyclic AMP levels and turning off cell
division, whereas lower doses indirectly induce pro-inflamma-
tory events.
My second comment has to do with antisense. Whereas the
delivery of antisense into the cell is a very appealing concept, it
turns out to be a tremendous problem. Moreover, the duration
of action, that is, the interval over which the target molecule is
actually suppressed, is also very limited; after 24 hours, you
have to give the antisense again. What's worse, repeated
injections of antisense might not be effective. So even though
the concept of using antisense molecules therapeutically is very
appealing on theoretical grounds, in practical terms, we're not
there yet.
DR. ABBOUD: Your first point is well taken. The concentra-
tion of the cytokine certainly has to be taken into consideration.
Certain cytokines have biphasic effects, depending on the
concentration being achieved. When cytokines are adminis-
tered systemically, the effects on the immune system in general
can differ from the effects exerted locally at target tissues such
as the glomerulus or interstitium. Your second point is also well
taken. The delivery system is a very important issue that is
being addressed by several groups. I would not be surprised if,
for therapeutic purposes, targeting proteins proved to be a lot
easier than targeting DNA.
DR. GIUSEPPE REMUZZL (Head, Laboratory of Kidney Dis-
eases, Mario Negri Institute for Pharmacological Research,
Bergamo, Italy): I'd like to make a general comment. I think we
are in a very early stage of this new game. We are dealing with
a complex problem of interaction between various cells and
multiple factors. Using techniques such as in-situ hybridization,
we find virtually everything we look for. I doubt that this is the
right approach to answering the questions we have. Let me use
an analogy. People have wondered for years about the relative
importance of coagulation factors, fibrin, and platelets in throm-
bosis, and in vasospasm in patients with myocardial infarction.
At least a partial answer to the problem was provided when it
became possible to pharmacologically inhibit a single factor at a
time. An example is inhibition of thromboxane by the adminis-
tration of low-dose aspirin. Using such information, researchers
have been able to reduce the effects of unstable angina and the
mortality rate from reinfarction. In my view, we should develop
pharmacologic tools, let's say molecules that bind to a specific
receptor, and see what happens, first using experimental ani-
mals and then human beings. In contrast to the problem with
myocardial infarction, however, in this case we are dealing with
a chronic process and not an acute phenomenon. To make
matters worse, these are relatively rare diseases, so it's very
difficult to conduct well-controlled studies that will provide
definitive answers. I think it's going to be very difficult to sort
all this out.
DR. ABBOUD: It is true that because multiple cytokines might
be expressed simultaneously, it is difficult to target a particular
cytokine for neutralization. However, serial biopsies from
experimental models of renal disease, as well as careful analysis
of human renal biopsies at different stages of glomerulonephri-
tis, might identify the predominant expression of a particular
cytokine or its receptor that might play a pathogenetic role. It
certainly is not going to be an easy task.
DR. STRIKER: I have two comments. First, I think it is very
important to try to find the right ligand-receptor interactions
and to try to locate the region or regions within a given molecule
that are responsible for different cell responses by the same
ligand-receptor interaction. Cross-talk between cells depends
on the cell, the receptor and, of course, the post-receptor
signaling, which can differ among individual cells. My second
comment is this: cell culture techniques give us very powerful
tools, but it's important for us to recognize that when we take
mesangial cells out of their natural habitat and put them in
culture, we are creating quite a "cultural shock." Mesangial
cells respond differently in vitro than they do in vivo. For
example, one finds different receptor numbers and the expres-
sion of different matrix molecules as a function of time [8]. It's
very important, therefore, that we clearly distinguish between
"mesangial cell" and "mesangial cell in culture." Cell culture
is a very nice way of looking at certain reactions, but the
difficulty in extrapolating from the mesangial cell to the glomer-
ulus and then to the overall function of the organism is going to
be a critical issue for us to keep in mind.
DR. ABBOUD: I agree.
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